This mutation pattern presumably reflects the differential selective advantages which tumours of different cellular origins can gain from constitutive activation of NRF2, which in turn suggests that electrophile-mediated activation of NRF2 by G12C inhibitors may also differentially impact disease progression across the three tumour types. This evidence concerns the gene NFE2L2 and neoplasm.